Oncolytics Biotech Inc - Company Profile

Powered by

All the data and insights you need on Oncolytics Biotech Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Oncolytics Biotech Inc Strategy Report

  • Understand Oncolytics Biotech Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Oncolytics Biotech Inc: Overview

Select Item

Oncolytics Biotech Inc (Oncolytics Biotech) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product candidate, pelareorep, is an unmodified reovirus that is an intraosseous (I-O) viral agent indicated for systemic administration for the treatment of hematological malignancies and solid tumors. It is advancing pelareorep as a combination with other products in various clinical phases for the treatment of metastatic breast cancer (BC), early-stage BC, pancreatic cancer, and relapsed or refractory multiple myeloma. Oncolytics Biotech is headquartered in Calgary, Alberta, Canada.

 Gain a 360-degree view of Oncolytics Biotech Inc and make more informed decisions for your business Gain a 360-degree view of Oncolytics Biotech Inc and make more informed decisions for your business Find out more
Headquarters Canada
Address 1167 Kensington Cres Nw Suite 210, Calgary Alberta Canada T2n 1x7, T2R0C5
Website www.oncolyticsbiotech.com
Telephone 1 403 6707377
No of Employees 29
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ONC (TSE)
EPS XYZ
Net Income (2022) XYZ -11.7% (2022 vs 2021)
Market Cap* $78.4M
   
   
* As of and is in US$
View Oncolytics Biotech Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Oncolytics Biotech Inc premium industry data and analytics

40+

Clinical Trials

Determine Oncolytics Biotech Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Catalyst Calendar

Proactively evaluate Oncolytics Biotech Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

7

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Pipeline Drugs

Identify which of Oncolytics Biotech Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline Product:-
BRACELET-1 = Pelareorep + Bavencio for Metastatic Breast Cancer
AWARE-1 = Pelareorep + Tecentriq for Early-stage Breast Cancer
XYZ
XYZ
XYZ
Understand Oncolytics Biotech Inc portfolio and identify potential areas for collaboration Understand Oncolytics Biotech Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Oncolytics Biotech Inc Zymeworks Inc Infinity Pharmaceuticals Inc IMV Inc AngioChem Inc
Headquarters Canada United States of America United States of America Canada Canada
City Calgary Middletown Cambridge Dartmouth Westmount
State/Province Alberta Delaware Massachusetts Nova Scotia Quebec
No. of Employees 29 272 30 63 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Wayne Pisano Chairman Executive Board 2013 -
Matt Coffey, Ph.D. President; Chief Executive Officer; Director Executive Board 2017 -
Kirk Look Chief Financial Officer Senior Management 2012 -
Thomas C. Heineman, M.D. Chief Medical Officer Senior Management 2021 -
Allison Hagerman Vice President - Product Development Senior Management 2010 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Oncolytics Biotech Inc key executives to enhance your sales strategy Gain insight into Oncolytics Biotech Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward